Page 4 - Fred Schwarzer News Today

IGM Biosciences Announces the Appointment of Chris H. Takimoto, M.D., Ph.D., F.A.C.P., as Chief Medical Officer MOUNTAIN VIEW, Calif., July 29, 2021 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of Chris H. Takimoto, M.D., Ph.D., F.A.C.P., to the role of Chief Medical Officer, effective today. Dr. Takimoto will be responsible for global development of...

Through a multi-institutional study, scientists have developed a new hybrid antibody that can neutralize over 20 variants of the SARS-CoV-2 virus, and shows promise as a potential treatment against COVID-19.

A nasal therapy, built upon on the application of a new engineered IgM antibody therapy for COVID-19, was more effective than commonly used IgG antibodies at neutralizing the COVID-19 virus in animal models, according to research recently published by The University of Texas Health Science Center at Houston (UTHealth), The University of Texas Medical Branch at Galveston (UTMB Health), the University of Houston, and IGM Biosciences, Inc.

A nasal therapy, built upon on the application of a new engineered IgM antibody therapy for COVID-19, was more effective than commonly used IgG antibodies at neutralizing the COVID-19 virus in animal models, according to research recently published by The University of Texas Health Science Center at Houston (UTHealth), The University of Texas Medical Branch at Galveston (UTMB Health), the University of Houston, and IGM Biosciences, Inc.

IGM Biosciences Appoints George Gauthier as Chief Commercial Officer Mr. Gauthier Brings 20 Years of Global Commercial Experience in the Life Sciences Industry April 12, 2021 07:00 ET | Source: IGM Biosciences IGM Biosciences Mountain View, California, UNITED STATES MOUNTAIN VIEW, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM a...

IGM Biosciences Appoints George Gauthier as Chief Commercial OfficerMr. Gauthier Brings 20 Years of Global Commercial Experience in the Life Sciences Industry - read this article along with other careers information, tips and advice on BioSpace

IGM Biosciences Appoints Lisa Decker, Ph.D., as Chief Business Officer – Ms. Decker Brings 20 Years of Development Experience in the Life Sciences Industry – March 15, 2021 07:00 ET | Source: IGM Biosciences IGM Biosciences Mountain View, California, UNITED STATES MOUNTAIN VIEW, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (IGM), a clinical-stage biotechnology company focused on creating and developing engineered ...

Medivir enters into exclusive licensing agreement with IGM Biosciences for birinapant - Medivir to Receive an Upfront Payment, as Well as Milestone Payments and Royalties - IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors News provided by Share this article Medivir AB (publ) (Nasdaq Stockholm: MVIR)  today announced that it has entered into an exclusive licensing agreement, through which IGM Biosciences, Inc. (Nasdaq: IGMS), will receive global, exclusiv...

Search jobs AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development SAN DIEGO--(BUSINESS WIRE)--AvantGen, Inc., a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development. Using its n...